HRI depletion cooperates with pharmacologic inducers to elevate fetal hemoglobin and reduce sickle cell formation

Increasing fetal hemoglobin (HbF) provides clinical benefit in patients with sickle cell disease (SCD). We recently identified heme-regulated inhibitor (HRI, EIF2AK1), as a novel HbF regulator. Because HRI is an erythroid-specific protein kinase, it presents a potential target for pharmacologic inte...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Blood Adv
Päätekijät: Peslak, Scott A., Khandros, Eugene, Huang, Peng, Lan, Xianjiang, Geronimo, Carly L., Grevet, Jeremy D., Abdulmalik, Osheiza, Zhang, Zhe, Giardine, Belinda M., Keller, Cheryl A., Shi, Junwei, Hardison, Ross C., Blobel, Gerd A.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Society of Hematology 2020
Aiheet:
Red Cells, Iron, and Erythropoiesis
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7509868/
https://ncbi.nlm.nih.gov/pubmed/32956454
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020002475
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia